Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes
Year: 2026
Type: article
Study design: Observational Study
Abstract: Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified 2045 patients with HR-MDS, of which 427 (21%) underwent SCT. The median post-SCT overall survival (OS) was 23.9 months, progression-free survival (PFS) was 14.4 months, 5-year cumulative incidence (CI) of relapse was 37%, and 5-year CI of treatment-related mortality (TRM) was 25%. There were no significant differences in OS, PFS, CI of relapse, or CI of TRM between age categories. Survival improved over the observation period (median 11.8 months in 2000-2010, 28.2 months in 2011-2016, and 40.2 months in 2017-2023; p = 0.01). By multivariate analysis, TP53 status was the most important predictor of post-SCT OS. Patients with TP53-wild type MDS had an OS of 69% at 5 years (HR for death 0.32 with SCT, p < 0.001). Patients with TP53 mutations had poor outcomes, with OS of 9.1 months in monoallelic (HR for death 0.88 with SCT, p = 0.69) and 6.8 months in biallelic (HR for death 0.76 with SCT, p = 0.14). SCT can lead to excellent long-term survival in TP53-wild type HR MDS.
Source: Blood Cancer Journal
Authors: Alexandre Bazinet, Alex Bataller, Kelly Chien, Koji Sasaki, Guillermo Montalban-Bravo, Danielle Hammond, Ian Bouligny, Mahesh Swaminathan, Wei Ying Jen, Eitan Kugler, Rashmi Kanagal-Shamanna, Tapan Kadia, Gautam Borthakur, Courtney DiNardo, Nicholas Short, Naveen Pemmaraju, Elias Jabbour, Naval Daver, Farhad Ravandi, Samuel Urrutia, Georgina Gener-Ricos, Julie Braish, Robert Briski, Juan Jose Rodriguez-Sevilla, Ziyi Li, Richard E. Champlin, Elizabeth J. Shpall, Amin Alousi, Betul Oran, Chitra Hosing, Jeremy L. Ramdial, Amanda Olson, Sherry Pierce, Julianne Chen, Hagop Kantarjian, Guillermo Garcia-Manero, Uday Popat
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Award: G1468253849
OpenAlex ID: W7141625703